Patients who take widely used kidney cancer drugs need to pay attention to recurrence

211
Patients who take widely used kidney cancer drugs need to pay attention to recurrence

Two widely used targeted therapy drugs approved by the FDA for the treatment of metastatic kidney cancer—sorafenib and sunitinib—are no more effective than a placebo in preventing return of the disease to increase life spans of patients suffering from advanced kidney cancer after surgery.

This is a new multi-institutional study published in the Lancet led by a researcher at the Abramson Cancer Center (ACC) of the University of Pennsylvania.

Researchers treated 1,943 patients in the United States and Canada with one year of sorafenib, sunitinib, or a placebo drug after surgery to remove their kidney tumors.

The study found no difference in median years of disease-free survival in the adjuvant setting (post-surgery): 5.8 years for sunitinib; 6.1 years for sorafenib; and 6.6 years for placebos.

Although the study did not establish a role for the drugs in the adjuvant setting, it has provided a definitive answer about their use that will help prevent any associated costs and toxic effects.

While surgery is typically the best initial treatment for renal tumors, surgical resection alone is not enough to prevent return of the disease in many patients.

Adjuvant therapies (applied after initial treatment with the goal of suppressing secondary tumor formation) are often needed to improve survival.

Sunitinib and sorafenib are examples of adjuvant therapies known as kinase inhibitors.

Kinases are proteins on or near the surface of cells; they help cancer grow and survive. Kinase inhibitors block the growth of kinases and associated blood vessels which nourish cancers.

Sorafenib and sunitinib, which are taken in pill form on a daily basis, are thought to block different kinases.

Both drugs have been shown to be effective when kidney cancer has spread to other parts of the body. Could they also be effective in preventing recurrence of the disease?

“The current standard of care for these patients is close observation,” Haas said.

“Unfortunately, we found that the use of sunitinib or sorafenib in this setting did not reduce the incidence of recurrence as compared to placebo. Fortunately, the use of these drugs in this setting did not appear to make the outcome of patients receiving them any worse.”

The findings closely mirror those of adjuvant trials in other tumors, such as breast and metastatic colorectal cancers, in which the benefits of bevacizumab in metastatic disease were not seen in the adjuvant setting.

This study is the first and largest trial on the effectiveness of these two kinase inhibitors in patients whose kidney tumors have been completely removed and who are at high risk for recurrence.

Haas said that there are other ongoing adjuvant trials investigating different lengths of therapy with sunitinib and sorafenib, as well as different kinase inhibitors.

The results of these investigations are not yet available and could have different results than the Penn study.

“It is important to support these trials so we learn how to better treat kidney cancer in the adjuvant setting,” she said.

Follow Knowridge Science Report on Facebook.


News source: Penn Health. The content is edited for length and style purposes.
Figure legend: This Knowridge.com image is for illustrative purposes only.